Beek Jeroen B. Van Sells 15,201 Shares of AlloVir, Inc. (NASDAQ:ALVR) Stock

AlloVir, Inc. (NASDAQ:ALVR) insider Beek Jeroen B. Van sold 15,201 shares of the firm’s stock in a transaction dated Tuesday, May 18th. The shares were sold at an average price of $22.80, for a total transaction of $346,582.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of ALVR traded down $1.01 during mid-day trading on Monday, hitting $22.98. The company had a trading volume of 315,977 shares, compared to its average volume of 292,994. The business’s 50-day simple moving average is $19.57 and its 200-day simple moving average is $21.92. AlloVir, Inc. has a 1-year low of $16.66 and a 1-year high of $48.96. The stock has a market cap of $1.50 billion, a PE ratio of -8.87 and a beta of 3.35.

AlloVir (NASDAQ:ALVR) last released its earnings results on Thursday, August 5th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.14). Research analysts forecast that AlloVir, Inc. will post -1.99 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the business. Great West Life Assurance Co. Can lifted its position in AlloVir by 115.0% during the second quarter. Great West Life Assurance Co. Can now owns 1,972 shares of the company’s stock valued at $39,000 after buying an additional 1,055 shares in the last quarter. SG Americas Securities LLC lifted its position in AlloVir by 10.7% during the second quarter. SG Americas Securities LLC now owns 11,354 shares of the company’s stock valued at $224,000 after buying an additional 1,095 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of AlloVir during the first quarter worth $32,000. Legal & General Group Plc lifted its position in shares of AlloVir by 41.5% during the second quarter. Legal & General Group Plc now owns 5,429 shares of the company’s stock worth $107,000 after purchasing an additional 1,591 shares in the last quarter. Finally, CNA Financial Corp lifted its position in shares of AlloVir by 14.5% during the second quarter. CNA Financial Corp now owns 13,405 shares of the company’s stock worth $265,000 after purchasing an additional 1,700 shares in the last quarter. 40.54% of the stock is currently owned by hedge funds and other institutional investors.

ALVR has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of AlloVir from a “hold” rating to a “sell” rating in a report on Wednesday, August 11th. SVB Leerink initiated coverage on shares of AlloVir in a report on Sunday, August 22nd. They set a “buy” rating for the company. Finally, Morgan Stanley lowered their price target on shares of AlloVir from $50.00 to $47.00 and set an “overweight” rating for the company in a report on Wednesday, August 18th.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.

Featured Article: Dividend Yield

Insider Buying and Selling by Quarter for AlloVir (NASDAQ:ALVR)

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.